证券代码：300878 证券简称：维康药业 公告编号：2025-008 二、董事会会议审议情况 （一）审议通过《关于公司 2024 年度总经理工作报告的议案》 与会董事认真听取了总经理刘洋先生所作的《2024 年度总经理工作报告》， 董事会认为 2024 年度公司经营管理层有效地执行了董事会和股东大会的各项决 议，该报告客观、真实地反映了经营管理层 2024 年度的主要工作。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 （二）审议通过《关于公司 2024 年度董事会工作报告的议案》 浙江维康药业股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江维康药业股份有限公司（以下简称"公司"）第四届董事会第五次会议 通知于 2025 年 4 月 17 日以电子邮件、专人送达或电话方式送达全体董事，本次 会议于 2025 年 4 月 27 日在浙江省丽水经济开发区遂松路 2 号二楼会议室以现场 结合通讯方式召开。本次会议由董事长刘洋先生主持，公司应出席董事 7 人，实 际出席董事 7 人。本 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-016 | 项 目 | 调整前金额 | 调整金额 | 调整后金额 | | --- | --- | --- | --- | | 其他应收款 | 11,554,269.55 | 17,544,475.55 | 29,098,745.10 | | 其他流动资产 | 23,927,015.34 | -564,510.96 | 23,362,504.38 | | 固定资产 | 529,833,584.44 | 29,610,251.59 | 559,443,836.03 | | 在建工程 | 301,907,569.27 | -31,475,373.90 | 270,432,195.37 | | 资产总计 | 2,046,636,530.88 | 15,114,842.28 | 2,061,751,373.16 | | 应交税费 | 5,437,966.56 | 14,321,505.02 | 19,759,471.58 | | 负债合计 | 639,227,731.24 | 14,321,505.02 | 653,549,236.26 | | 盈余公积 ...

Financial Performance - The company's revenue for Q1 2025 was ¥69,775,938.28, a decrease of 65.10% compared to ¥199,953,044.93 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥9,854,658.34, representing a decline of 140.50% from a profit of ¥24,334,978.24 in the previous year[5] - The basic earnings per share for the period was -¥0.07, down 141.18% from ¥0.17 in the same period last year[5] - Net profit for the period was a loss of ¥9,706,327.17 compared to a profit of ¥24,389,323.96 in the previous period, indicating a significant downturn[18] - The company's net profit margin and future guidance were not explicitly detailed in the provided documents[12] Cash Flow and Operating Activities - The net cash flow from operating activities improved to -¥6,488,555.71, a 60.53% increase compared to -¥16,439,476.59 in the same period last year[5] - Operating cash flow net amount was a negative ¥6,488,555.71, an improvement from a negative ¥16,439,476.59 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥259,807,484.08 from ¥225,921,021.74, showing a positive change[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,638,649,780.40, a decrease of 0.83% from ¥1,652,323,039.56 at the end of the previous year[5] - The total assets of Zhejiang Weikang Pharmaceutical Co., Ltd. as of March 31, 2025, amounted to CNY 1,638,649,780.40, a decrease from CNY 1,652,323,039.56 at the beginning of the period[14] - Total current liabilities decreased to CNY 228,091,892.00 from CNY 240,381,545.98, a reduction of about 5.1%[15] - Long-term borrowings increased to CNY 197,372,877.74 from CNY 186,619,205.86, reflecting an increase of approximately 5.7%[15] - The total equity attributable to the parent company decreased to CNY 1,147,811,901.37 from CNY 1,157,666,559.71, a decline of about 0.9%[16] Sales and Expenses - The cash received from sales of goods and services was ¥58,473,216.71, a decrease of 54.16% from ¥127,565,675.80 in the previous year[9] - Total operating revenue decreased to ¥69,775,938.28 from ¥199,953,044.93, representing a decline of approximately 65% year-over-year[17] - Total operating costs decreased to ¥79,431,824.89 from ¥173,888,443.65, a reduction of about 54% year-over-year[17] - The company reported a decrease in sales expenses to ¥30,418,191.53 from ¥52,336,889.43, a reduction of approximately 42% year-over-year[17] - Research and development expenses slightly decreased to ¥2,671,042.00 from ¥2,971,220.93, a decline of about 10% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,248, with the largest shareholder holding 60.89% of the shares[10] Asset Impairment and Credit Quality - The company reported a significant increase in asset impairment losses, which rose by 4354.98% to ¥1,541,958.53 compared to -¥34,612.01 in the previous year[9] - The company incurred a credit impairment loss of ¥4,867,447.87 compared to a gain of ¥4,978,010.08 in the previous period, indicating a significant shift in credit quality[18] Government Support and Investments - The company received government subsidies amounting to ¥2,060,338.52 during the reporting period[6] - The total cash inflow from investment activities was ¥44,625,315.68, a decrease from ¥250,969,467.74 in the previous period[21] Market and Product Development - There were no significant updates on new product developments or market expansions mentioned in the conference call[12] - The company did not report any mergers or acquisitions during this period[12]

Financial Performance - The company reported a significant decline in performance, primarily due to the transfer of its wholly-owned subsidiaries, resulting in a non-recurring investment income of RMB 88.25 million, while also recognizing fixed asset impairment of RMB 76.20 million[3]. - Product sales revenue and gross margin decreased due to a drop in product prices and underperformance in sales and management[4]. - The company's operating revenue for 2024 was ¥351,198,567.67, a decrease of 32.41% compared to ¥519,621,071.15 in 2023[21]. - The net loss attributable to shareholders for 2024 was ¥-147,426,253.43, representing a significant increase of 1,546.42% from a loss of ¥-8,038,557.83 in 2023[21]. - The net cash flow from operating activities for 2024 was ¥-27,173,007.35, a decline of 146.62% from ¥58,289,136.41 in 2023[21]. - The total assets at the end of 2024 were ¥1,652,323,039.5, down 19.86% from ¥2,046,636,530.88 at the end of 2023[21]. - The net assets attributable to shareholders decreased by 16.75% to ¥1,157,666,559.7 at the end of 2024 from ¥1,389,807,852.57 at the end of 2023[21]. - The company reported a basic and diluted earnings per share of ¥-1.03 for 2024, a decrease of 1,616.67% from ¥-0.06 in 2023[21]. - The weighted average return on equity for 2024 was -11.75%, compared to -0.58% in 2023[21]. - The company reported a net profit attributable to shareholders of -¥191,521,798.32 in Q4, highlighting substantial losses in the last quarter[28]. Investment and R&D - The company plans to enhance its profitability by advancing core R&D projects, including innovative traditional Chinese medicine products and improved formulations, with a focus on market-ready short-term projects[6]. - The company emphasizes R&D investment and talent acquisition, establishing multiple research platforms to enhance its core competitiveness in the pharmaceutical field[40]. - The company is currently advancing several key projects, including the "Bone Spur Capsule," which is under review by the National Pharmacopoeia Committee[52]. - The "Yinhuang Diban" is in the clinical trial phase, having completed Phase II trials and currently in communication for Phase III trials[52]. - The company is conducting research on multiple traditional Chinese medicine formulations, including "Jichuan Decoction" and "Wenjing Decoction," which are in various stages of development[52]. - The company holds 37 drug approval numbers, with key products like Yinhuang Diban and Luohongmycin Soft Capsules having invention patents and core technologies[56]. - The company has established multiple research platforms, including provincial high-tech enterprise R&D centers and has received various provincial science and technology awards[56]. - The company plans to submit applications for several new traditional Chinese medicine products, enhancing its product line and potential revenue streams[80]. Market Strategy and Expansion - Efforts will be made to include more core products in the national medical insurance directory, which is expected to boost demand and market expansion[7]. - The company aims to increase production capacity for existing products and new product commercialization through investments in modern facilities[7]. - A nationwide marketing network has been established, with plans to further enhance its coverage and the professionalism of the sales team to support sustainable growth[7]. - The company is currently enhancing its research plans based on prior communications with CDE regarding the Silver Yellow Inhalation Solution[56]. - The company aims to strengthen the development of traditional Chinese medicine in response to national policies promoting healthcare and innovation in the pharmaceutical industry[36]. - The company is focused on maintaining the rights and interests of all shareholders through diligent oversight[166]. - The company plans to continue expanding its market presence and product development in the pharmaceutical sector[98]. Human Resources and Management - The company will strengthen human resource management and talent acquisition to support its rapid development and maintain a stable workforce[9]. - The management team has extensive experience in the pharmaceutical industry, contributing to effective market development and product quality control[60]. - The company has established an independent human resources department with a complete personnel management system[134]. - The company has a well-structured internal management organization, including a shareholders' meeting, board of directors, and supervisory board, ensuring independent operational authority[136]. - The company has a total of 650 employees, including 232 production personnel, 252 sales personnel, 87 technical personnel, 22 financial personnel, and 57 administrative personnel[172]. - The company emphasizes talent cultivation and has developed a comprehensive training system to enhance employee skills and meet the company's development needs[175]. Financial Management and Compliance - The company corrected prior financial statements due to a misappropriation of funds totaling ¥157,300,000, which included ¥54,000,500 of raised funds[22]. - The company plans to continue monitoring the use of raised funds and has transferred ¥54,000,500 back to the designated account[22]. - The company has a well-developed new drug research and development system, emphasizing market research and strict control at all stages, while increasing investment in R&D and talent acquisition to mitigate product development risks[117]. - The company has established a comprehensive quality management system based on drug quality risk assessment to ensure compliance with safety, efficacy, and quality control requirements throughout the production process[116]. - The company is actively monitoring changes in national pharmaceutical policies to proactively develop response measures[113]. - The company has been under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[184]. - The company emphasizes compliance with laws and regulations, ensuring accurate and timely information disclosure to enhance operational transparency[188]. Shareholder and Governance - The board approved a profit distribution plan, proposing a cash dividend of RMB 1.4 per 10 shares, with no bonus shares issued[9]. - The company announced a change in leadership with Liu Yang being elected as Chairman and General Manager effective May 20, 2024[142]. - The company has a complete governance structure with independent directors and a supervisory board[141]. - The company has committed to not engage in direct or indirect competition with its own subsidiaries to protect its interests[194]. - The company will avoid similar investment projects to prevent competition with its own interests[194]. - The company has a strategy in place to address any potential misleading information in its public offering documents[200]. - The company is committed to establishing an investor compensation fund to address potential losses[200]. Operational Challenges - The company is facing challenges due to declining product prices and management performance, leading to adjustments in production plans[72]. - The company has reported a total of 5.5 million yuan in unused raised funds that have been idle for over two years[95]. - The investment in the pharmaceutical health industry park project has not met expected returns primarily due to lower-than-expected sales during the period[98]. - The company is currently advancing core R&D projects, including innovative traditional Chinese medicine products, with significant investment in research and development[105]. - The company faces policy risks related to the ongoing reforms in the medical and pharmaceutical sectors, which may impact its operations if not addressed timely[112].

| 投资主体 | 受托方 | 关联 | 产品名称 | 产品类型 | 委托理 财金额 | 起始日期 | | 到期日期 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | | | （万元） | | | | 收益率 | | 浙江维康 药业股份 | 东亚前海 证券有限 | 无 | 东亚前海证券 | 固定收益 | 500 | | | 按周赎回 每周一、 | 最终收益 以实际支 | | | | | 祥裕周周享 1 | 类集合资 | | 2025 4 | 年 | | | | | | | 号集合资产管 | 产管理计 | | 月 1 | 日 | | | | 有限公司 | 责任公司 | | | | | | | 周三 | 付为准 | | | | | 理计划 | 划 | | | | | | 一、理财产品的基本情况 二、审批程序 公司第四届董事会第四次会议、第四届监事会第四次会议，审议通过了《关 于使用闲置自有资金进行委托理财的议案》，本次购买理财产品的额度和期限均 在审批范围内，无需另行提交董事会或者股东大会审议。 证券代 ...

证券代码：300878 证券简称：维康药业 公告编号：2025-005 浙江维康药业股份有限公司 关于获得二冬汤颗粒上市申请受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日获得国家药品监督 管理局发出的二冬汤颗粒药品注册上市许可申请《受理通知书》。现将相关情况 公告如下： 一、受理通知书主要内容 产品名称：二冬汤颗粒 申请事项：境内生产药品注册上市许可 特此公告。 申请人：浙江维康药业股份有限公司 受理号：CXZS2500013 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以 受理。 二、二冬汤颗粒的相关情况 二冬汤颗粒，润肺清胃。主治上消。症见烦渴不止，小便频数，脉数无力等。 三、同类药品的情况 截至本公告披露日，经查询国家药品监督管理局网站，取得该品种的药品批 准文号的企业有：江西药都樟树制药有限公司、贵州威门药业股份有限公司。 四、对公司的影响及风险提示 根据国家相关法规规定，上述药品已获得注册申请受理，报送国家药监局药 品审评中心进行审评审批。上述药品获得受理通知书 ...

浙江维康药业股份有限公司 关于公司产品中选全国中成药采购联盟集中带量采购(首批扩围 接续)的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300878 证券简称：维康药业 公告编号：2025-004 2024 年血塞通分散片销售额约为 2600 万元，其中每盒 40 片规格的血塞通 分散片销售额约为 480 万元，占公司 2024 年度营业收入的比重分别为 7%、1.3% （该数据未经审计）。 采购周期中，医疗机构将优先使用本次药品集中采购中选药品，并确保完成 约定采购量。若公司后续签订采购合同并实施，将有利于进一步扩大相关产品的 销售规模，提高市场占有率，提升公司品牌影响力，对公司的未来经营业绩具有 积极的影响。 三、风险提示 血塞通分散片的采购协议签订等后续事项及对公司的影响程度尚具有不确 定性。敬请广大投资者审慎决策，注意投资风险。 特此公告。 浙江维康药业股份有限公司 董事会 近日，浙江维康药业股份有限公司（以下简称"公司"）参与全国中成药采购 联盟集中带量采购的投标工作。根据湖北医保服务平台于 2025 年 2 月 10 日发布 的 ...

Financial Performance - The company expects a net loss of RMB 110 million to RMB 150 million for the year 2024, a decrease of 1268% to 1766% compared to the previous year's loss of RMB 8.04 million [3]. - The expected net loss after deducting non-recurring gains is RMB 190 million to RMB 240 million, a decline of 653% to 852% from last year's loss of RMB 25.22 million [3]. Non-Recurring Gains - The company sold its wholly-owned subsidiaries engaged in pharmaceutical retail, generating an investment income of approximately RMB 90 million, which is classified as non-recurring gains [5]. Impairment and Depreciation - Fixed asset impairment provisions amounting to RMB 87.42 million were recorded due to underutilization of production capacity [5]. - The depreciation of fixed assets increased significantly due to the transfer of fixed assets from the first and second phases of the pharmaceutical health industry park, further affecting profits [6]. Sales and Revenue Challenges - The decline in product prices and subpar sales and management performance led to a decrease in both sales revenue and gross margin [6]. - The introduction of drug traceability codes and changes to product instructions resulted in increased product returns, negatively impacting revenue and profit, especially in Q4 2024 [6]. Regulatory Investigation - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [7].

证券代码：300878 证券简称：维康药业 公告编号：2024-089 浙江维康药业股份有限公司 公司指定信息披露媒体为《中国证券报》《上海证券报》《证券日报》《证 券时报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn），公司发布的信 息请以在上述指定媒体、网站刊登的公告为准。敬请广大投资者注意投资风险。 特此公告。 浙江维康药业股份有限公司 董事会 2024 年 12 月 27 日 关于公司及实际控制人收到中国证券监督管理委员 会《立案告知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）及公司实际控制人刘忠良 先于 2024 年 12 月 27 日收到中国证券监督管理委员会（以下简称"中国证监会"） 下发的《中国证券监督管理委员会立案告知书》（编号：证监立案字 01120240040 号、编号：证监立案字 01120240041 号），因涉嫌信息披露违法违规，根据《中 华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会 决定对公司及公司实际控制人刘忠良先生立案。 在 ...

财联社12月29日电，维康药业公告，公司及实际控制人刘忠良于2024年12月27日收到中国证监会下发的 《立案告知书》，因涉嫌信息披露违法违规，中国证监会决定对公司及刘忠良立案。 目前公司生产经营情况正常，该事项不会对公司日常经营活动产生重大影响。 在立案调查期间，公司及刘忠良将积极配合中国证监会的相关工作。 ...